Kailas M. Karande, Shivaji P. Gawade
Kailas M. Karande1, Shivaji P. Gawade2
1Department of Pharmaceutics, Satara College of Pharmacy, Satara, India.
2Principal, Late Narayandas Bhawandas Chhabada Institute of Pharmacy, Raigaon, Satara.
Volume - 14,
Issue - 3,
Year - 2021
Prevalence of silver nanoparticles in various sectors including healthcare is abundantly increasing. Several research articles are published focusing the synthesis and silver nanoparticle’s activities. Least literature is available about the long-term or short-term health consequences of these nanoparticles. While ionic and nanoparticulate silver are employed in several applications, information on their undesirable health effects are truly extremely scarce and roughly all concluded simply acute effects caused by short-range contact to very elevated doses. Few consequences are argyria and argyrosis, (bluish grey discolorations of skin and eye, respectively). Both situations are caused by the contact to a high dose of silver or to constant short doses of silver used for some months or even years. In contexts of this, we have worked on in silico ADME profile of silver nanoparticles and its complexation with ibuprofen using Gastroplus software. In order to make sure the reliability of in silico model used, we have validated it with the independent data from the literature. Pharmacokinetic parameters, like %Fa, %FDp, %F, Cmax, Tmax, AUC were determined and revealed the superiority of complex against the pure drug.
Cite this article:
Kailas M. Karande, Shivaji P. Gawade. In silico Biopharmaceutical Prediction of silver Nanoparticle and Ibuprofen Complex. Research J. Pharm. and Tech 2021; 14(3):1736-1740. doi: 10.5958/0974-360X.2021.00309.7
1. Mathur P, Jha S, Ramteke S, Jain NK. Pharmaceutical aspects of silver nanoparticle. Artificial cells, Nanomedicine, and Biotechnology. 2018 Oct 31; 46 (sup1): 115-26.
2. Clark NJ, Boyle D, Handy RD. An assessment of the dietary bioavailability of silver nanomaterials in rainbow trout using an ex vivo gut sac technique. Environmental Science: Nano. 2019; 6(2): 646-60.
3. Park K, Park EJ, Chun IK, Choi K, Lee SH, Yoon J, Lee BC. Bioavailability and toxicokinetics of citrate-coated silver nanoparticle in rats. Archives of Pharmacal Research. 2011 Jan 1; 34(1): 153-8.
4. Dziendzikowska K, Gromadzka‐Ostrowska J, Lankoff A, Oczkowski M, Krawczyńska A, Chwastowska J, Sadowska‐Bratek M, Chajduk E, Wojewodzka M, Dušinská M, Kruszewski M. Time‐dependent biodistribution and excretion of silver nanoparticle in male Wistar rats. Journal of Applied Toxicology. 2012 Nov; 32(11): 920-8.
5. Van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, Serrano-Rojero CS, Gremmer ER, Mast J, Peters RJ, Hollman PC, Hendriksen PJ. Distribution, elimination, and toxicity of silver nanoparticle and silver ions in rats after 28-day oral exposure. ACS Nano. 2012 Aug 28; 6(8): 7427-42.
6. Park K. Toxicokinetic differences and toxicities of silver nanoparticle and silver ions in rats after single oral administration. Journal of Toxicology and Environmental Health, Part A. 2013 Nov 17; 76(22): 1246-60.
7. Van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, Serrano-Rojero CS, Gremmer ER, Mast J, Peters RJ, Hollman PC, Hendriksen PJ. Distribution, elimination, and toxicity of silver nanoparticle and silver ions in rats after 28-day oral exposure. ACS Nano. 2012 Aug 28; 6(8): 7427-42.
8. Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, Choi BS, Lim R, Chang HK, Chung YH, Kwon IH. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticle in Sprague-Dawley rats. Inhalation Toxicology. 2008 Jan 1; 20(6): 575-83.
9. Simulations Plus. GastroPlus™ Version 9.7 Manual. Simulations Plus; Lancaster, CA, USA: 2015.
10. Albert KS, Gernaat CM. Pharmacokinetics of ibuprofen. The American Journal of Medicine. 1984 Jul 13; 77(1): 40-6.